Haloprogin

This classification denotes an anti-infective agent with the molecular formula C9H4Cl3IO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AIU7053OWL, chemically known as 2,4,5-trichlorophenyl iodopropargyl ether but generally known as haloprogin, which bears US NIH Compound Identifier 3561. European Medicines Agency schedules Haloprogin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08008MIG. The term HALOPROGIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). World Health Organization schedules haloprogin in its Anatomical Therapeutic Chemical (ATC) Classification. HALOPROGIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule haloprogin under HS 29093090 and SITC 51616. As of Q4 2014, HALOPROGIN remains the US FDA Preferred Term for this commodity. Haloprogin bears US NLM identifiers UMLS ID C0720811 and NCI Concept Code C65842. SMILES: IC#CCOC1C(CL)CC(CL)C(CL)C1.